CONSTELLATION TECHNOLOGIES LIMITED — Regulatory Filings 2007

Dec 20, 2007

==> picture [96 x 77] intentionally omitted <==

21 December 2007

Agenix Part Of Successful Consortium Which Wins Monoclonal Antibody Grant

Agenix today announced that it was part of a successful consortium that has been awarded an Industry Cooperative Innovation Program (ICIP) Grant entitled “Production of Monoclonal Antibodies” from AusIndustry, a division of the Department of Industry, Tourism and Resources. The ICIP grant consortium members are Acyte Biotech Pty Ltd, Biopharmaceuticals Australia, and Agen Biomedical Ltd.

The grant research work will be led by Acyte and will address the need to accelerate monoclonal antibody production from the research bench to the clinic by optimizing and selecting appropriate cell lines which can be used for antibody production. Acyte will utilize its innovative cell expression technology to isolate and identify high yielding cell lines in a rapid fashion, potentially reducing the time taken for this aspect of biopharmaceutical development from many months to a few weeks. Agen will contribute materials, technical characterization of expression products and commercially focused direction. Biopharmaceuticals Australia will leverage outcomes to assist other organisations translate R&D opportunities into commercial prospects.

Agen’s Research and Product Development Director, Dr Mike Gerometta said: “We are pleased to be a part of this successful grant which will address an important need to improve rapid and cost-effective production of monoclonal antibodies from mammalian cell culture. This grant is evidence of Agenix’s aim to remain on the cutting edge of Australia’s monoclonal antibody innovation, after guiding ThromboView[®] through preclinical and Phase II clinical development.”

Acyte CEO, Professor Peter Gray stated: “Currently, optimization of expression and production methods for promising biopharmaceutical candidates is often outsourced to overseas groups, with time and expense impacts for the product development cycle. Building Australian capability in this domain is critical to facilitating the translation of promising bench research into lead candidates, ready for early stage clinical trials.”

BioPharmaceuticals Australia aims to develop world-class contract manufacturing facilities to service the needs of this rapidly growing sector. General Manager David Hughes said, “This is a great example of how Australian players can build on each others’ strengths to support commercial development of products expressed in mammalian cells. We look forward to encouraging many more such collaborations”.

ENDS

For more information, please contact:

Mr Neil Leggett CEO and Managing Director Agenix Limited Ph: +61 408 151 270